3 results
Primary end point• Progression-free survival (PFS) per ICR central assessmentSecondary end point• Objective response rate (ORR)• Disease control rate (DCR)• Overall survival (OS)• PFS according to Investigator assessment of radiologic images•…
Primary:To assess the tolerability of asciminib versus nilotinib with respect to the time to discontinuation of study treatment due to adverse event.Secondary:• Efficacy of asciminib versus nilotinib in terms of discontinuation due to lack of…
The primary objective of this study is to characterize the pharmacokinetic (PK) profile of asciminib in pediatric patients, with the goal of identifying the pediatric formulation dose (fed) leading to asciminib exposure comparable to 40 mg BID in…